• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Stoke Therapeutics, Inc. - Common Stock (NQ:STOK)

    35.54 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Apr 15, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 58
    Open 35.54
    Bid (Size) 14.22 (200)
    Ask (Size) 56.56 (100)
    Prev. Close 35.54
    Today's Range 35.54 - 35.54
    52wk Range 7.310 - 40.22
    Shares Outstanding 44,188,534
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    Stoke Therapeutics Stock Up 340% as Chair Sells $174K in Shares ↗
    This biotech innovator in genetic disease therapies reported a notable insider sale amid a year of dramatic share price gains. 
    Via The Motley Fool
    Topics Regulatory Compliance

    Performance

    YTD
    +15.0%
    +15.0%
    1 Month
    +4.7%
    +4.7%
    3 Month
    +14.8%
    +14.8%
    6 Month
    -0.2%
    -0.2%
    1 Year
    +358.6%
    +358.6%

    More News

    Read More
    News headline image
    Wave Life Sciences Shakes Biotech Sector with Breakthrough Obesity Data: A New Era for ‘Quality’ Weight Loss
    Via MarketMinute
    News headline image
    Stoke Therapeutics CMO Sells $457,000 in Stock Amid 300% Rally ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
    From Biogen Inc.
    Via GlobeNewswire
    News headline image
    Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million ↗
    Via The Motley Fool
    News headline image
    Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120% ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025 ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26% ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA)
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
    From Stoke Therapeutics, Inc.
    Via Business Wire
    Top movers in Monday's pre-market session ↗
    Via Chartmill
    News headline image
    Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    Stoke Therapeutics' Chief Medical Officer Sold Over 5,000 Shares in the Company. Should Shareholders Sell? ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Curious about the stocks that are showing activity after the closing bell on Tuesday? ↗
    Via Chartmill
    News headline image
    Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
    From Biogen Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Stoke Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Stoke Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Stoke Therapeutics, Inc. - Common Stock trade on?
    Stoke Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Stoke Therapeutics, Inc. - Common Stock?
    The ticker symbol for Stoke Therapeutics, Inc. - Common Stock is STOK on the Nasdaq Stock Market
    What is the current price of Stoke Therapeutics, Inc. - Common Stock?
    The current price of Stoke Therapeutics, Inc. - Common Stock is 35.54
    When was Stoke Therapeutics, Inc. - Common Stock last traded?
    The last trade of Stoke Therapeutics, Inc. - Common Stock was at 04/15/26 04:00 PM ET
    What is the market capitalization of Stoke Therapeutics, Inc. - Common Stock?
    The market capitalization of Stoke Therapeutics, Inc. - Common Stock is 1.57B
    How many shares of Stoke Therapeutics, Inc. - Common Stock are outstanding?
    Stoke Therapeutics, Inc. - Common Stock has 2B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.